Zydus Lifesciences moves up on getting USFDA’s final approval for Ammonium Lactate Cream
Zydus Lifesciences is currently trading at Rs. 910.65, up by 5.80 points or 0.64% from its previous closing of Rs. 904.85 on the BSE.
The scrip opened at Rs. 904.80 and has touched a high and low of Rs. 916.00 and Rs. 904.25 respectively. So far 3360 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 933.40 and Rs. 882.00 respectively. The current market cap of the company is Rs. 91788.66 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream, 12%).
Ammonium lactate cream, 12% is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris. It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften skin, and decrease skin scaling.
Ammonium lactate cream will be manufactured at the group’s topical manufacturing site at Changodar, Ahmedabad, and distributed by Viona Pharmaceuticals Inc. Ammonium lactate cream had annual sales of $15 million in the United States (IQVIA MAT December 2025). The group now has 430 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.
